Files and links (2)
The CEDAR Study - A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice1.49 MB
Published VersionCC BY V4.0, Open Access
Journal article
The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
International Journal of Rheumatology, Vol.2017, pp.1-9
2017
PMCID: PMC5463140
PMID: 28630629
Abstract
Objectives. To observe the choices of conventional disease modifying antirheumatic drugs (cDMARDs) and biologic DMARDs (bDMARDs) in the management of rheumatoid arthritis (RA) in Australian routine clinical practice, to assess treatment survival and determine the effect of cDMARDs/bDMARDs on disease activity. Methods. Routinely collected, deidentified clinical data was sourced from 20 Australian rheumatology practices. RA patients aged ≥18 years, who had received cDMARDs/bDMARDs and a recorded subsequent visit, were included. A linear mixed model was used to determine the change over time and the percentage reduction in disease activity was summarized. Results. 12,526 RA patients were included: 72% females, mean age 62 years. cDMARDs and bDMARDs were used in 92% and 30% of patients, respectively. The most commonly prescribed cDMARD was methotrexate (76% patients); median time to stopping treatment was 337 months [95% CI: 279–ND]. Etanercept was the most commonly prescribed bDMARD (12% patients); median time to stopping treatment was 79 months [95% CI: 57–93]. Of 5,341 patients with a first change in medication (cDMARD or bDMARD), 87% had therapy escalation and 13% deescalation. Reduction in DAS28-ESR, 6-month post-DMARDs initiation ranged from 3%, adalimumab, to 14%, leflunomide and tocilizumab. Conclusions. In this large Australian cohort of unselected community RA patients, the choices of cDMARDs/bDMARDs are aligned with current international guidelines.
Details
- Title
- The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
- Authors
- Lynden Roberts (Author) - Monash UniversityKathleen Tymms (Author) - Australian National UniversityJulien de Jager (Author) - Pacific Private Clinic, Southport, QLD, AustraliaGeoffrey Littlejohn (Author) - Monash UniversityHedley Griffiths (Author) - Barwon Rheumatology Service, Geelong, VIC, AustraliaDave Nicholls (Author) - Coast Joint Care and University of the Sunshine Coast, Sunshine Coast, QLD, AustraliaPaul Bird (Author) - UNSW AustraliaJennifer Young (Author) - Roche Products Pty Limited, Sydney, NSW, AustraliaJulie Hill (Author)Jane Zochling (Author) - Menzies Institute for Medical Research, Hobart, TAS, Australia
- Publication details
- International Journal of Rheumatology, Vol.2017, pp.1-9
- Publisher
- Hindawi Limited
- Date published
- 2017
- DOI
- 10.1155/2017/1201450
- ISSN
- 1687-9279; 1687-9260
- PMID
- 28630629; PMC5463140
- Copyright note
- Copyright © 2017 Lynden Roberts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Organisation Unit
- UniSC Clinical Trials Centre; University of the Sunshine Coast, Queensland
- Language
- English
- Record Identifier
- 99523208202621
- Output Type
- Journal article
Metrics
19 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web Of Science research areas
- Rheumatology
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites